114 related articles for article (PubMed ID: 26665182)
1. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C.
Da Silva DM; Woodham AW; Rijkee LK; Skeate JG; Taylor JR; Koopman ME; Brand HE; Wong MK; McKee GM; Salazar AM; Kast WM
Papillomavirus Res; 2015 Dec; 1():12-21. PubMed ID: 26665182
[TBL] [Abstract][Full Text] [Related]
2. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.
Da Silva DM; Woodham AW; Skeate JG; Rijkee LK; Taylor JR; Brand HE; Muderspach LI; Roman LD; Yessaian AA; Pham HQ; Matsuo K; Lin YG; McKee GM; Salazar AM; Kast WM
Clin Immunol; 2015 Dec; 161(2):197-208. PubMed ID: 26360252
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.
Da Silva DM; Woodham AW; Naylor PH; Egan JE; Berinstein NL; Kast WM
J Interferon Cytokine Res; 2016 May; 36(5):291-301. PubMed ID: 26653678
[TBL] [Abstract][Full Text] [Related]
4. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Mar; 182(5):2919-28. PubMed ID: 19234187
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.
Da Silva DM; Movius CA; Raff AB; Brand HE; Skeate JG; Wong MK; Kast WM
Virology; 2014 Mar; 452-453():279-86. PubMed ID: 24606705
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.
Woodham AW; Raff AB; Raff LM; Da Silva DM; Yan L; Skeate JG; Wong MK; Lin YG; Kast WM
J Immunol; 2014 May; 192(10):4748-57. PubMed ID: 24719459
[TBL] [Abstract][Full Text] [Related]
7. The L1 major capsid protein of HPV16 differentially modulates APC trafficking according to the vaccination or natural infection context.
Herman L; Hubert P; Herfs M; Kustermans G; Henrotin Y; Bousarghin L; Boniver J; Delvenne P
Eur J Immunol; 2010 Nov; 40(11):3075-84. PubMed ID: 21061438
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity.
Yin W; Duluc D; Joo H; Xue Y; Gu C; Wang Z; Wang L; Ouedraogo R; Oxford L; Clark A; Parikh F; Kim-Schulze S; Thompson-Snipes L; Lee SY; Beauregard C; Woo JH; Zurawski S; Sikora AG; Zurawski G; Oh S
Cancer Immunol Res; 2016 Oct; 4(10):823-834. PubMed ID: 27485136
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro.
Woodham AW; Raff AB; Da Silva DM; Kast WM
Methods Mol Biol; 2015; 1249():135-49. PubMed ID: 25348303
[TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
[TBL] [Abstract][Full Text] [Related]
11. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.
de Jong A; van der Burg SH; Kwappenberg KM; van der Hulst JM; Franken KL; Geluk A; van Meijgaarden KE; Drijfhout JW; Kenter G; Vermeij P; Melief CJ; Offringa R
Cancer Res; 2002 Jan; 62(2):472-9. PubMed ID: 11809698
[TBL] [Abstract][Full Text] [Related]
12. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells.
Fausch SC; Da Silva DM; Kast WM
Vaccine; 2005 Feb; 23(14):1720-9. PubMed ID: 15705478
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
16. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx.
Hoffmann TK; Arsov C; Schirlau K; Bas M; Friebe-Hoffmann U; Klussmann JP; Scheckenbach K; Balz V; Bier H; Whiteside TL
Int J Cancer; 2006 Apr; 118(8):1984-91. PubMed ID: 16284959
[TBL] [Abstract][Full Text] [Related]
17. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
18. Polyinosinic-polycytidylic acid-mediated stimulation of human gammadelta T cells via CD11c dendritic cell-derived type I interferons.
Kunzmann V; Kretzschmar E; Herrmann T; Wilhelm M
Immunology; 2004 Jul; 112(3):369-77. PubMed ID: 15196204
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
20. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
